Synlett, Inhaltsverzeichnis Synlett 2014; 25(12): 1705-1708DOI: 10.1055/s-0034-1378275 letter © Georg Thieme Verlag Stuttgart · New York An Efficient Approach to the Synthesis of Alkyl 7-Hydroxy-1-oxo-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine-8-carboxylates via a One-Pot, Three-Component Reaction Abdolali Alizadeh* Department of Chemistry, Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran Fax: +98(21)88006544 eMail: abdol_alizad@yahoo.com eMail: aalizadeh@modares.ac.ir , Marziyeh Hossein Abadi Department of Chemistry, Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran Fax: +98(21)88006544 eMail: abdol_alizad@yahoo.com eMail: aalizadeh@modares.ac.ir , Rashid Ghanbaripour Department of Chemistry, Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran Fax: +98(21)88006544 eMail: abdol_alizad@yahoo.com eMail: aalizadeh@modares.ac.ir › Institutsangaben Artikel empfehlen Abstract Artikel einzeln kaufen Alle Artikel dieser Rubrik Abstract An efficient synthesis of alkyl 7-hydroxy-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-8-carboxylate derivatives by reaction between diamines, dialkyl acetylenedicarboxylates, and alkyl or aryl glyoxales is reported. Ease of handling, easy purification, and good yields are the main advantages of the presented method. Key words Key wordsdiamine - dialkyl acetylenedicarboxylate - glyoxale - alkyl 7-hydroxy-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-8-carboxylate - one-pot, three-component reaction Volltext Referenzen References and Notes 1a Comprehensive Heterocyclic Chemistry II. Katritzky AR, Rees CW, Scriven EF. V. Pergamon Press; Oxford: 1996 1b Craig PN In Comprehensive Medicinal Chemistry . Vol. 8. Drayton CJ. Pergamon; New York, NY: 1991 2a Hansch C, Sammes PG, Taylor JB. Comprehensive Medicinal Chemistry . Vol. 2. Chapt. 7. Pergamon; Oxford: 1990 2b Erlanson DA, McDowell RS, O’Brien T. J. Med. Chem. 2004; 4: 3463 2c Butler MS. J. Nat. Prod. 2004; 67: 2141 3 Denny WA, Rewcastle GW, Baguley BC. J. Med. Chem. 1990; 33: 814 4 Lehuede J, Fauconneau B, Barrier L, Ourakow M, Piriou A, Vierfond JM. Eur. J. Med. Chem. 1999; 34: 991 5 Del Poeta M, Schell WA, Dykstra CC, Jones S, Tidwell RR, Czarny A, Bajic M, Kumar A, Boykin D, Perfect JR. Antimicrob. Agents Chemother. 1998; 4: 2495 6a Jonas R, Klockow M, Lues I, Pruecher H, Schliep HJ, Wurziger H. Eur. J. Med. Chem. 1993; 28: 129 6b von der Saal W, Hoelck JP, Kampe W, Mertens A, Mueller-Beckmann B. J. Med. Chem. 1989; 32: 1481 7 Ferraris D, Ficco RP, Dain D, Ginski M, Lautar S, Lee-Wisdom K, Liang S, Lin Q, Lu MX. C, Morgan L, Thomas B, Williams LR, Zhang J, Zhou Y, Kalish VJ. Bioorg. Med. Chem. 2003; 11: 3695 8 Bovy PR, Reitz DB, Collins JT, Chamberlain TS, Olins GM, Corpus VM, McMahon EG, Palomo MA, Koepke JP, Smits GJ, McGraw DE, Gaw JF. J. Med. Chem. 1993; 36: 101 9 Trushkov IV, Nevolina TA, Shcherbinin VA, Sorotskaya LN, Butin AV. Tetrahedron Lett. 2013; 54: 3974 10a Smith ND, Huang D, Cosford ND. P. Org. Lett. 2002; 4: 3537 10b Suryavanshi PA, Sridharan V, Menéndez JC. Tetrahedron 2013; 69: 5401 10c Chong Q, Xin X, Wang C, Wu F, Wan B. Tetrahedron 2014; 70: 490 10d Butin AV, Nevolina TA, Shcherbinin VA, Uchuskin MG, Serdyuk OV, Trushkov IV. Synthesis 2010; 2969 10e El Kaim L, Grimaud L, Wagschal S. Chem. Commun. 2011; 47: 1887 10f Stroganova TA, Butin AV, Vasilin VK, Nevolina TA, Krapivin GD. Synlett 2007; 1106 10g Hashmi AS. K, Pankajakshan S, Rudolph M, Enns E, Bander T, Rominger F, Frey W. Adv. Synth. Catal. 2009; 351: 2855 10h Petronijevic FR, Wipf P. J. Am. Chem. Soc. 2011; 133: 7704 11 Peresada VP, Medvedev OS, Likhosherstov AM, Skoldinov AP. Khim. Farm. Zh. 1987; 21: 1054 ; Chem. Abstr. 1988, 108, 68298g 12 Seredenin SB, Voronina TA, Beshimov A, Peresada VP, Likhosherstov AM. RU 2099055, 1997 ; Chem. Abstr. 1998, 128, 290245j 13 Seredenin SB, Voronina TA, Likhosherstov AM, Peresada YP, Molodavkin GM, Halikas JA. US 5378846, 1995 ; Chem. Abstr. 1995, 123, 83350w 14 Likhosherstov AM, Filippova OV, Peresada VP, Kryzhanovskii SA, Vititnova MB, Kaverina NV, Reznikov KM. Pharm. Chem. J. 2003; 37: 6 15 Merla B, Christoph T, Oberboersch S, Schiene K, Bahrenberg G, Frank R, Kuehnert S, Schroeder W. WO 2008046581, 2008 ; Chem. Abstr. 2009, 148, 495982g 16 Negoro T, Murata M, Ueda S, Fujitani B, Ono Y, Kuromiya A, Komiya M, Suzuki K, Matsumoto JI. J. Med. Chem. 1998; 41: 4118 17 Merla B, Christoph T, Oberboersch S, Schiene K, Bahrenberg G, Frank R, Kuehnert S, Schroeder W. WO 2008046582, 2008 ; Chem. Abstr. 2008, 148, 472076a 18a Tilvi S, Moriou C, Martin MT, Gallard JF, Sorres J, Patel K, Petek S, Debitus C, Ermolenko L, Al-Mourabit A. J. Nat. Prod. 2010; 73: 720 18b Al-Mourabit A, Zancanella MA, Tilvic S, Romo D. Nat. Prod. Rep. 2011; 28: 1229 18c Papeo G, Gómez-Zurita Frau MA, Borghi D, Varasi M. Tetrahedron Lett. 2005; 46: 8635 19a Hewlett NM, Tepe JJ. Org. Lett. 2011; 13: 4550 19b Cheng G, Wang X, Bao H, Cheng C, Liu N, Hu Y. Org. Lett. 2012; 14: 1062 19c Bhowmik S, Kumar AK. S, Batra S. Tetrahedron Lett. 2013; 54: 2251 19d Bandini M, Bottoni A, Eichholzer A, Miscione GP, Stenta M. Chem. Eur. J. 2010; 16: 12462 19e Voskressensky LG, Titov AA, BorisovaT N, Listratova AV, Borisov RS, Kulikova LN, Varlamov AV. Tetrahedron 2010; 66: 5140 19f Trost BM, Osipov M, Dong G. J. Am. Chem. Soc. 2010; 132: 15800 19g Mukherjee S, Sivappa R, Yousufuddin M, Lovely CJ. Org. Lett. 2010; 12: 4940 19h Imaoka T, Akimoto T, Iwamoto O, Nagasawa K. Chem. Asian J. 2010; 5: 1810 19i Trost BM, Osipov M, Dong G. Org. Lett. 2010; 12: 1276 20a Alizadeh A, Ghanbaripour R, Zhu LG. Synlett 2013; 24: 2124 20b Alizadeh A, Ghanbaripour R, Zhu LG. Synth. Commun. 2013; 43: 2575 20c Alizadeh A, Ghanbaripour R. Helv. Chim. Acta 2013; 96: 473 20d Alizadeh A, Sedighian H, Bayat F. Synlett 2014; 24: 389 20e Alizadeh A, Ghanbaripour R, Zhu LG. Tetrahedron 2014; 70: 2048 20f Alizadeh A, Zohreh N. ACS Comb. Sci. 2013; 15: 278 21 To a solution of ethylenediamine (1 mmol) in EtOH (2 mL), dimethyl acetylenedicarboxylate (1 mmol) was added dropwise at r.t. After 30 min, methylglyoxal (1 mmol) and PTSA (0.1 mmol) were added to the reaction mixture, and the solution was stirred for 2.5 h at reflux conditions. Upon completion (3 h), monitored by TLC, the solvent was cooled at an ice bath, and the precipitate was filtered to afford the pure products 3a–f. Methyl 7-Hydroxy-6-methyl-1-oxo-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazine-8-carboxylate (3a) Pale orange powder; 0.156 g, 70% yield; mp 187–189 °C. IR (KBr): 3211 (NH), 3099 (OH), 1715 (CO2Me), 1675 (NCO), 1219 and 1146 (CO) cm–1. 1H NMR (400 MHz, CDCl3): δ = 2.20 (s, 3 H, CH3), 3.65–3.68 (m, 2 H, CH2NH), 3.94 (s, 3 H, OMe), 3.95 (t, 3 J HH = 5.6 Hz, 2 H, CH2N), 7.28 (s, 1 H, NH), 8.39 (s, 1 H, OH). 13C NMR (100 MHz, CDCl3): δ = 7.9 (CH3), 39.3 (CH2NH), 41.6 (CH2N), 52.1 (OMe), 103.4 (C6), 114.4 (C8), 118.2 (C8a), 145.9 (COH), 159.3 (CO2CH3), 167.5 (NCO). MS: m/z = 225 [M+ + 1], 224 [M+], 192, 164, 136, 123, 107, 95, 79, 66, 53. Anal. Calcd (%) for C10H12N2O4: C, 53.57; H, 5.39; N, 12.40. Found: C, 53.51; H, 5.46; N, 12.38. Ethyl 7-Hydroxy-6-methyl-1-oxo-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazine-8-carboxylate (3b) Pale brown powder; 0.178 g, 74%; mp 178–179 °C. IR (KBr): 3393 (NH), 3193 (OH), 1710 (CO2Et), 1668 (NCO), 1335, 1225 and 1150 (CO) cm–1. 1H NMR (400 MHz, CDCl3): δ = 1.34 (t, 3 J HH = 7.0 Hz, 3 H, CH2CH 3), 2.12 (s, 3 H, CH3), 3.56–3.59 (m, 2 H, CH2NH), 3.87 (t, 3 J HH = 5.7 Hz, 2 H, CH2N), 4.32 (q, 3 J HH = 7.0 Hz, 2 H, CH 2CH3), 7.01 (s, 1 H, NH), 8.28 (s, 1 H, OH). 13C NMR (100 MHz, CDCl3): δ = 7.9 (CH3), 14.2 (CH3), 39.3 (CH2NH), 41.6 (CH2N), 60.9 (OCH2), 103.9 (C6), 114.3 (C8), 118.3 (C8a), 145.8 (COH), 159.2 (CO2Et), 166.9 (NCO). MS: m/z = 239 [M+ + 1], 238 [M+], 192, 164, 136, 123, 107, 95, 80, 67, 53. Anal. Calcd (%) for C11H14N2O4: C, 55.46; H, 5.92; N, 11.76. Found: C, 55.36; H, 5.87; N, 11.82. Methyl 7-Hydroxy-1-oxo-6-1,2,3,4-tetrahydrophenyl-pyrrolo[1,2-a]pyrazine-8-carboxylate (3c) Pale yellow powder; 0.238 g, 83% yield; mp 90–92 °C. IR (KBr): 3350 (NH), 3235 (OH), 1706 (CO2Me), 1664 (NCO), 1580 and 1481 (Ar), 1348, 1225 and 1141 (CO) cm–1. 1H NMR (300.13 MHz, CDCl3): δ = 3.69–3.65 (m, 2 H, CH2NH), 3.98 (s, 3 H, OMe), 4.11 (t, 3 J HH = 5.9 Hz, 2 H, CH2N), 6.59 (s, 1 H, NH), 7.35–7.39 (m, 1 H, CH para of Ph), 7.44–7.50 (m, 4 H, 2 × CH ortho and 2 × CH meta of Ph), 8.80 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 39. 7 (CH2NH), 43.1 (CH2N), 52.2 (OMe), 103.7 (C6), 118.7 (C8), 119.6 (C8a), 128.0 (CH para of Ph), 128.3 (C ipso ), 128.7 (2 × CH ortho of Ph), 129.4 (2 × CH meta of Ph), 146.6 (COH), 158.9 (CO2Me), 167.6 (NCO). MS: m/z = 287 [M+ + 1], 287 [M+], 279, 262, 254, 219, 205, 167, 149, 132, 121, 113, 104, 93, 83, 71, 57. Anal. Calcd (%) for C15H14N2O4: C, 62.93; H, 4.93, N, 9.79. Found: C, 62.97; H, 5.01; N, 9.86. Ethyl 7-Hydroxy-1-oxo-6-1,2,3,4-tetrahydrophenyl-pyrrolo[1,2-a]pyrazine-8-carboxylate (3d) Pale yellow powder; 0.198 g 66% yield; mp 213–214 °C. IR (KBr): 3184 (NH), 3064 (OH), 1708 (CO2Et), 1665 (NCO), 1580 and 1481 (Ar), 1300, 1239 and 1197 (CO) cm–1. 1H NMR (400 MHz, CDCl3): δ = 1.45 (t, 3J HH = 7.2 Hz, 3H, CH2CH 3), 3.10–3.64 (m, 2 H, CH2NH), 4.11 (t, 3 J HH = 5.6 Hz, 2 H, CH2N), 4.45 (q, 3J HH = 7.2 Hz, 2 H, CH 2CH3), 7.12 (s, 1 H, NH), 7.36–7.40 (m, 1 H, CH para of Ph), 7.46–7.51 (m, 4 H, 2 × CH ortho and 2 × CH meta of Ph), 8.75 (s, 1 H, OH). 13C NMR (100 MHz, CDCl3): δ = 14.2 (CH3), 39.6 (CH2NH), 43.1 (CH2N), 61.1 (OCH2), 104.1 (C6), 118.6 (C8), 119.8 (C8a), 127.9 (CH para of Ph), 128.4 (C ipso ), 128.7 (2 × CH ortho of Ph), 129.4 (2 × CH meta of Ph), 146.4 (COH), 159.2 (CO2Et), 166.9 (NCO). MS: m/z = 301 [M+ + 1], 300 [M+], 254, 225, 211, 198, 183, 169, 155, 141, 128, 115, 104, 95, 77, 67, 53. Anal. Calcd (%) for C16H16N2O4: C, 63.99; H, 5.37, N, 9.33. Found: C, 64.01; H, 5.49; N, 9.30. Methyl 7-Hydroxy-1-oxo-6-(4-chlorophenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-8-carboxylate (3e) Pale beige powder; 0.245 g, 86% yield; mp 203–204 °C. IR (KBr): 3325 (NH), 3200 (OH), 1710 (CO2Me), 1660 (NCO), 1574 and 1481 (Ar), 1299, 1233 and 1138 (C–O) cm–1. 1H NMR (400 MHz, CDCl3): δ = 3.63–3.68 (m, 2 H, CH2NH), 3.99 (s, 3 H, OMe), 4.10 (t, 3 J HH = 5.8 Hz, 2 H, CH2N), 6.84 (s, 1 H, NH), 7.41 (d, 3 J HH = 8.8 Hz, 2 H, 2 × CH of Ar), 7.46 (d, 3 J HH = 8.4 Hz, 2 H, 2 × CH of Ar), 8.85 (s, 1 H, OH). 13C NMR (100 MHz, CDCl3): δ = 39.6 (CH2NH), 43.1 (CH2N), 52.3 (OMe), 103.7 (C6), 117.5 (C8), 120.0 (C8a), 126.7 (C ipso ), 129.0 (2 × CH of Ar), 130.7 (2 × CH of Ar), 133.9 (C ipso Cl), 146.8 (COH), 158.9 (CO2Me), 167.5 (NCO). MS: m/z = 322 [M+ + 2], 321 [M+ + 1], 320 [M+], 288, 262, 253, 232, 189, 175, 162, 151, 137, 123, 111, 95, 80, 67, 53. Anal. Calcd (%) for C15H13ClN2O4: C, 66.02; H, 5.30; N, 13.39. Found: C, 65.98; H, 5.45; N, 13.43. Ethyl 7-Hydroxy-1-oxo-6-(4-chlorophenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-8-carboxylate (3f) Yellow powder; 0.223 g, 66% yield; mp 243–244 °C. IR (KBr): 3181 (NH), 3073 (OH), 1713 (CO2Et), 1677 (NCO), 1566 and 1476 (Ar), 1302, 1224 and 1150 (CO) cm–1. 1H NMR (400 MHz, CDCl3): δ = 1.45 (t, 3 J HH = 7.0 Hz, 3 H, CH2CH 3), 3.63–3.68 (m, 2 H, CH2NH), 4.10 (t, 3 J HH = 5.8 Hz, 2 H, CH2N), 4.46 (q, 3 J HH = 7.0 Hz, 2 H, CH 2CH3), 6.51 (s, 1 H, NH), 7.41 (d, 3 J HH = 8.8 Hz, 2 H, 2 × CH of Ar), 7.46 (d, 3 J HH = 8.8 Hz, 2 H, 2 × CH of Ar), 8.84 (s, 1 H, OH). 13C NMR (100 MHz, CDCl3): δ = 14.2 (CH3), 39.7 (CH2NH), 43.1 (CH2N), 61.3 (OCH2), 104.2 (C6), 117.4 (C8), 120.1 (C8a), 126.8 (C ipso ), 129.0 (2 × CH of Ar), 130.5 (2 × CH of Ar), 133.9 (C ipso Cl), 146.7 (COH), 158.7 (CO2Et), 166.9 (NCO). MS: m/z = 336 [M+ + 2], 335 [M+ + 1], 334 [M+], 288, 259, 245, 232, 203, 189, 175, 162, 138, 123, 111, 95, 80, 67, 53. Anal. Calcd (%) for C16H15ClN2O4: C, 57.41; H, 4.52; N, 8.37. Found: C, 57.32; H, 4.47; N, 8.31.
